Supporting table 2 Pharmacological characterization of DOR-eGFP mice

	+/+	*n*	+/eGFP	*n*	eGFP/eGFP	*n*	p
Saturation experiment: [^{3}H]-naltrindole[a]							
K_D (nM)	0.16 ± 0.03	7	0.12 ± 0.01	7	0.10 ± 0.02	7	0.14
Bmax (pmol/mg prot)	0.16 ± 0.02	7	0.25 ± 0.02***	7	0.32 ± 0.01***	7	< 0.001
Agonist-induced G proteins activation[b]							
EC_{50} (nM)							
Met-enkephalin	500.27 ± 44.37	4	425.32 ± 36.33	4	583.35 ± 61.43	4	0.12
Deltorphin II	47.51 ± 29.47	6	34.93 ± 12.24	7	18.18 ± 6.80	8	0.47
SNC80	122.14 ± 9.46	5	104.40 ± 4.05	6	122.83 ± 9.74	6	0.27
DAMGO	180.45 ± 13.82	4	175.75 ± 17.65	4	228.90 ± 10.84	4	0.05
U50,488	116.83 ± 29.06	3	133.55 ± 36.61	4	185.53 ± 66.11	3	0.59
Emax (% basal)							
Met-enkephalin	285.47 ± 17.22	4	307.35 ± 6.29	4	331.27 ± 13.81	4	0.10
Deltorphin II	115.40 ± 2.89	8	122.75 ± 2.79*	8	138.50 ± 5.35**	8	< 0.01
SNC80	152.18 ± 5.28	5	203.18 ± 3.11***	6	269.77 ± 10.75***	6	< 0.001
DAMGO	251.05 ± 24.9	4	242.90 ± 16.48	4	242.63 ± 16.96	4	0.94
U50,488	134.86 ± 6.30	4	127.96 ± 2.21	4	133.02 ± 4.28	4	0.56

[a]Affinity of [^{3}H]-naltrindole (K_D) and number of sites (Bmax) are shown. [b]G proteins activation was quantified using the [^{35}S]-GTPγS binding assay. Potencies (EC_{50}) and efficacies (Emax) are shown. Reported values are mean ± sem. n indicates the number of independent experiments. One-way ANOVA was used to analyze the effect of the genotype (p values). For p values < 0.05, Bonferroni post-hoc test was used to compare heterozygous and homozygous mutant mice to wild-type mice (* p < 0.05, ** p < 0.01, *** p < 0.001).